Data gathered: December 26
AI Stock Analysis - Pliant Therapeutics (PLRX)
Analysis generated December 6, 2024. Powered by Chat GPT.
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Fibrosis is a serious and often life-threatening condition that occurs when the normal tissue structure in an organ is destroyed and replaced by scar tissue. The company aims to target the cellular mechanisms that cause fibrosis using proprietary technologies.
Stock Alerts - Pliant Therapeutics (PLRX)
 |
Pliant Therapeutics | December 26 Price is up by 5.3% in the last 24h. |
|
Pliant Therapeutics | December 19 Price is down by -5.1% in the last 24h. |
|
Pliant Therapeutics | December 17 Price is up by 5% in the last 24h. |
|
Pliant Therapeutics | December 13 Price is down by -5.1% in the last 24h. |
Alternative Data for Pliant Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 10 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 7,000 | Sign up | Sign up | Sign up |
| Employee Rating | 94 | Sign up | Sign up | Sign up |
| Google Trends | 7 | Sign up | Sign up | Sign up |
| Patents | 27 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 4 | Sign up | Sign up | Sign up |
| Facebook Followers | 80 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,173 | Sign up | Sign up | Sign up |
| Twitter Followers | 459 | Sign up | Sign up | Sign up |
| Twitter Mentions | 23 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 101 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 182 | Sign up | Sign up | Sign up |
About Pliant Therapeutics
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.
| Price | $14.03 |
| Target Price | Sign up |
| Volume | 353,470 |
| Market Cap | $821M |
| Year Range | $10.52 - $15.7 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Pliant Therapeutics (NASDAQ:PLRX) and Bionomics (NASDAQ:BNOX) Head-To-Head AnalysisDecember 26 - ETF Daily News |
|
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives $40.50 Consensus Price Target from AnalystsDecember 25 - ETF Daily News |
|
Intech Investment Management LLC Makes New Investment in Pliant Therapeutics, Inc. (NASDAQ:PLRX)December 8 - ETF Daily News |
|
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of “Buy” from AnalystsNovember 28 - ETF Daily News |
|
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Sold by Quest Partners LLCNovember 26 - ETF Daily News |
 |
Pliant Therapeutics to Participate in Upcoming Investor EventsNovember 20 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 14M | -14M | -58M | -62M | 0.000 |
| Q2 '24 | 0 | 15M | -15M | -56M | -60M | -0.920 |
| Q1 '24 | 0 | 15M | -16M | -47M | -52M | -0.780 |
| Q4 '23 | 4.8M | 14M | -14M | -41M | -47M | -0.690 |
| Q3 '23 | 0 | 15M | -16M | -41M | -48M | -0.700 |
Insider Transactions View All
| Ouimette Mike filed to sell 94,044 shares at $11.6. July 12 '24 |
| Hull Hans filed to sell 227,494 shares at $11.6. July 12 '24 |
| Coulie Bernard filed to sell 482,936 shares at $11.6. July 12 '24 |
| Cummings Keith Lamont filed to sell 282,115 shares at $11.6. July 12 '24 |
| Lefebvre Eric filed to sell 213,052 shares at $11.6. July 12 '24 |
Similar companies
Read more about Pliant Therapeutics (PLRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Pliant Therapeutics?
The Market Cap of Pliant Therapeutics is $821M.
What is the current stock price of Pliant Therapeutics?
Currently, the price of one share of Pliant Therapeutics stock is $14.03.
How can I analyze the PLRX stock price chart for investment decisions?
The PLRX stock price chart above provides a comprehensive visual representation of Pliant Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Pliant Therapeutics shares. Our platform offers an up-to-date PLRX stock price chart, along with technical data analysis and alternative data insights.
Does PLRX offer dividends to its shareholders?
As of our latest update, Pliant Therapeutics (PLRX) does not offer dividends to its shareholders. Investors interested in Pliant Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Pliant Therapeutics?
Some of the similar stocks of Pliant Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.